Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Subviral herpes simplex vaccine.

L Kutinovà, V Slichtová, V Vonka

    Developments in Biological Standardization
    |January 1, 1982
    PubMed
    Summary

    A novel herpes simplex virus type 1 (HSV-1) vaccine, free of viral DNA, effectively induced neutralizing antibodies and protected mice against HSV-1 and HSV-2 infections, also limiting latent infection establishment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Relationship of Kynurenine and Neopterin Levels and Their Association with a Selection of Other Immune Markers in Chronic Myeloid Leukaemia Patients.

    Folia biologica·2017
    Same author

    Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3.

    Cancer gene therapy·2014
    Same author

    IL-2 as adjuvant for vaccination with cells malignantly converted by HPV 16 or 3-MC.

    International journal of oncology·2011
    Same author

    Transient transformation of mammalian cells by MN protein, a tumor-associated cell adhesion molecule with carbonic anhydrase activity.

    International journal of oncology·2011
    Same author

    Expression of soluble TGF-β receptor II by recombinant Vaccinia virus enhances E7 specific immunotherapy of HPV16 tumors.

    Neoplasma·2011
    Same author

    [Will vaccines appear on the scene of oncology in the near future?].

    Vnitrni lekarstvi·2010

    Area of Science:

    • Virology
    • Immunology
    • Vaccine Development

    Background:

    • Herpes simplex virus (HSV) infections pose a significant public health challenge.
    • Development of effective vaccines against HSV remains a critical research area.
    • Existing vaccines often face challenges with efficacy and safety.

    Purpose of the Study:

    • To develop and evaluate an experimental subunit vaccine for herpes simplex virus type 1 (HSV-1).
    • To assess the vaccine's immunogenicity and protective capabilities against HSV infections in animal models.
    • To establish a method for quantifying neutralizing antigens in the vaccine preparation.

    Main Methods:

    • Preparation of a subunit HSV-1 vaccine from infected human diploid cells, devoid of viral DNA.
    • Development of a chromium release inhibition test (CRIT) to quantify neutralizing antigens.
    • Administration of the vaccine to animals and subsequent challenge with HSV-1 and HSV-2.

    Main Results:

    • The vaccine successfully induced neutralizing antibody formation in various animal models.
    • Vaccinated mice demonstrated significant protection against intraperitoneal challenge with both HSV-1 and HSV-2.
    • Vaccine administration markedly restricted the establishment of latent HSV infections in mice.
    • A strong correlation was observed between vaccine immunogenicity and neutralizing antigen content determined by CRIT.

    Conclusions:

    • The experimental subunit HSV-1 vaccine is immunogenic and protective against both HSV types.
    • The developed CRIT assay effectively correlates with vaccine efficacy.
    • This DNA-free subunit vaccine shows promise for preventing HSV infections and limiting latency.

    Related Experiment Videos